NCT00580125 - Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Schizophrenia

Interventions

DRUG

PF-00217830

PF-00217830 5 mg, oral capsule, once daily for 21 days

OTHER

Placebo

Placebo, oral capsule, once daily for 21 days

DRUG

Aripiprazole

Aripiprazole 15 mg, oral capsule, once daily for 21 days

DRUG

PF-00217830

PF-00217830 15 mg, oral capsule, once daily for 21 days

DRUG

PF-00217830

PF-00217830 2 mg, oral capsule, once daily for 21 days

Trial Locations (26)

11203

Pfizer Investigational Site, Brooklyn

20016

Pfizer Investigational Site, Washington D.C.

48201

Pfizer Investigational Site, Detroit

49115

Pfizer Investigational Site, Dnipropetrovsk

61018

Pfizer Investigational Site, Kharkiv

61068

Pfizer Investigational Site, Kharkiv

63033

Pfizer Investigational Site, Florissant

63304

Pfizer Investigational Site, Saint Charles

83037

Pfizer Investigational Site, Donetsk

90502

Pfizer Investigational Site, Torrance

91045

Pfizer Investigational Site, Luhansk

92845

Pfizer Investigational Site, Garden Grove

95006

Pfizer Investigational Site, Simferopol

115522

Pfizer Investigational Site, Moscow

141371

Pfizer Investigational Site, Khot'kovo

188357

Pfizer Investigational Site, Gatchina District

190121

Pfizer Investigational Site, Saint Petersburg

194214

Pfizer Investigational Site, Saint Petersburg

575001

Pfizer Investigational Site, Mangalore

63044-2588

Pfizer Investigational Site, Bridgeton

560 034

Pfizer Investigational Site, Bangalore

576 102

Pfizer Investigational Site, Udupi

411 004

Pfizer Investigational Site, Pune

411 030

Pfizer Investigational Site, Pune

02660

Pfizer Investigational Site, Kiev

01030

Pfizer Investigational Site, Kyiv